Literature DB >> 18179137

Loss of OPCML expression and the correlation with CpG island methylation and LOH in ovarian serous carcinoma.

H Chen1, F Ye, J Zhang, W Lu, Q Cheng, X Xie.   

Abstract

PURPOSE: To detect the expression of OPCML in ovarian serous carcinoma and investigate the correlation with CpG island methylation and LOH of OPCML.
METHODS: 20 normal tissues, 75 ovarian serous tumors, three cell lines, SKOV-3, CAOV3 and 3AO, were detected in OPCML expression by RT-PCR, CpG island methylation by methylation-sensitive restriction enzyme-PCR, and LOH analysis at four microsatellite marks (D11S4085, D11S1320, D11S874 and D11S969).
RESULTS: Loss of OPCML expression in ovarian serous carcinomas was significantly higher than in ovarian adenomas and normal tissues. OPCML expression was detectable in 3AO, but not in SKOV-3 and CAOV3. CpG island methylation was found in 53.4% of the carcinomas, while in none of the adenomas or normal tissues. Meanwhile, CpG island methylation was detectable in SKOV-3 and CAOV3, but not in 3AO. The correlation between CpG island methylation and loss of OPCML expression was found in carcinomas. The LOH rate at D11S4085 in carcinomas was significantly higher than that for adenomas and normal tissues. LOH at D11S4085 was also correlated with loss of OPCML expression.
CONCLUSIONS: These results indicate that loss of OPCML expression occurs frequently in ovarian serous carcinoma. CpG island methylation and LOH are probably two mechanisms of OPCML inactivation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18179137

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  10 in total

1.  OPCML is frequently methylated in human colorectal cancer and its restored expression reverses EMT via downregulation of smad signaling.

Authors:  Chunhong Li; Liping Tang; Lijuan Zhao; Lili Li; Qian Xiao; Xinrong Luo; Weiyan Peng; Guosheng Ren; Qian Tao; Tingxiu Xiang
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

2.  Reduction of pancreatic acinar cell tumor multiplicity in Dnmt1 hypomorphic mice.

Authors:  Shirley Oghamian; Nicole M Sodir; Muhammad U Bashir; Hui Shen; Andrea E Cullins; Cindy A Carroll; Pratima Kundu; Darryl Shibata; Peter W Laird
Journal:  Carcinogenesis       Date:  2011-03-01       Impact factor: 4.944

3.  Allelic skewing of DNA methylation is widespread across the genome.

Authors:  Leonard C Schalkwyk; Emma L Meaburn; Rebecca Smith; Emma L Dempster; Aaron R Jeffries; Matthew N Davies; Robert Plomin; Jonathan Mill
Journal:  Am J Hum Genet       Date:  2010-02-12       Impact factor: 11.025

4.  Expression of ovarian tumour suppressor OPCML in the female CD-1 mouse reproductive tract.

Authors:  Jean S Fleming; H James McQuillan; Melanie J Millier; Grant C Sellar
Journal:  Reproduction       Date:  2009-01-27       Impact factor: 3.906

5.  Expression and promoter methylation status of OPCML and its functions in the inhibition of cell proliferation, migration, and invasion in breast cancer.

Authors:  Bin Lian; Hong Li; Yaobang Liu; Dahai Chai; Yali Gao; Yangyang Zhang; Jia Zhou; Jinping Li
Journal:  Breast Cancer       Date:  2020-10-27       Impact factor: 4.239

6.  Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation.

Authors:  Anni Niskakoski; Sippy Kaur; Synnöve Staff; Laura Renkonen-Sinisalo; Heini Lassus; Heikki J Järvinen; Jukka-Pekka Mecklin; Ralf Bützow; Päivi Peltomäki
Journal:  Epigenetics       Date:  2014-12       Impact factor: 4.528

Review 7.  Cross-Talk between Fibroblast Growth Factor Receptors and Other Cell Surface Proteins.

Authors:  Marta Latko; Aleksandra Czyrek; Natalia Porębska; Marika Kucińska; Jacek Otlewski; Małgorzata Zakrzewska; Łukasz Opaliński
Journal:  Cells       Date:  2019-05-14       Impact factor: 6.600

8.  Serum cell-free DNA methylation of OPCML and HOXD9 as a biomarker that may aid in differential diagnosis between cholangiocarcinoma and other biliary diseases.

Authors:  Wiphawan Wasenang; Ponlatham Chaiyarit; Siriporn Proungvitaya; Temduang Limpaiboon
Journal:  Clin Epigenetics       Date:  2019-03-04       Impact factor: 6.551

9.  Inactivating mutations and X-ray crystal structure of the tumor suppressor OPCML reveal cancer-associated functions.

Authors:  James R Birtley; Mohammad Alomary; Elisa Zanini; Jane Antony; Zachary Maben; Grant C Weaver; Claudia Von Arx; Manuela Mura; Aline T Marinho; Haonan Lu; Eloise V N Morecroft; Evdoxia Karali; Naomi E Chayen; Edward W Tate; Mollie Jurewicz; Lawrence J Stern; Chiara Recchi; Hani Gabra
Journal:  Nat Commun       Date:  2019-07-17       Impact factor: 14.919

10.  The OPCML tumor suppressor functions as a cell surface repressor-adaptor, negatively regulating receptor tyrosine kinases in epithelial ovarian cancer.

Authors:  Arthur B McKie; Sebastian Vaughan; Elisa Zanini; Imoh S Okon; Louay Louis; Camila de Sousa; Mark I Greene; Qiang Wang; Roshan Agarwal; Dmitry Shaposhnikov; Joshua L C Wong; Hatice Gungor; Szymon Janczar; Mona El-Bahrawy; Eric W-F Lam; Naomi E Chayen; Hani Gabra
Journal:  Cancer Discov       Date:  2012-02       Impact factor: 39.397

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.